Advertisement
AMGN vs NVS
Which Stock Would AI Choose? Amgen Inc. (AMGN) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- AMGN recently beat second-quarter revenue and earnings estimates and raised full-year guidance, while NVS posted only modest sales growth and reaffirmed a forecast for a decline in core operating income.
- Amgen's growth is being driven by cardiometabolic and rare-disease drugs such as Repatha, Evenity, and Uplizna, whereas Novartis is leaning on oncology and neuroscience products including Kisqali, Kesimpta, and Pluvicto.
- Novartis has absorbed two high-profile late-stage trial failures in recent weeks, pressuring sentiment, while Amgen's obesity program faces its own pipeline setbacks balanced by broad commercial momentum.
- Both stocks carry "Hold" consensus ratings, but their relative performance and risk profiles have diverged noticeably in recent market activity.
- Investors comparing defensive, dividend-paying pharmaceutical leaders may find the contrast in momentum, pipeline risk, and market positioning useful for portfolio decisions.
Introduction
Amgen Inc. and Novartis AG are two of the world's largest and most established biopharmaceutical companies, yet they sit at very different points in their business cycles. Amgen is a U.S.-based biotechnology leader with a broad portfolio spanning cardiovascular, oncology, inflammation, and rare disease therapies, while Novartis, headquartered in Switzerland, is a diversified innovative medicines company concentrated in oncology, immunology, neuroscience, and cardiovascular care. This stock comparison is relevant for investors weighing relative performance, growth durability, and pipeline risk between two defensive healthcare franchises. Both offer substantial dividends and global scale, but recent events have widened the gap in how the market perceives their near-term momentum and positioning.
AMGN Overview and Recent Performance
Amgen is a pioneer in biotechnology-based human therapeutics, with blockbuster franchises in bone health, cholesterol management, inflammation, and oncology, supplemented by a growing biosimilar business. In recent weeks, Amgen has demonstrated resilient operational momentum. Its most recent quarterly results showed revenue rising roughly 9% to about $10 billion, with adjusted earnings per share (EPS) coming in comfortably ahead of consensus. Management also lifted its full-year outlook, a signal that growth drivers are performing broadly.
Much of that strength is concentrated in newer therapies. Repatha, a cholesterol-lowering medicine, has been growing at a double-digit pace and is now Amgen's top growth driver, while Evenity and the rare-disease drug Uplizna have also posted strong gains. These advances are offsetting erosion in older products such as Prolia, which faces intensifying biosimilar competition. On the pipeline side, Amgen discontinued one obesity candidate but continues to advance MariTide, its lead weight-loss asset, with pivotal data expected in 2027. This mix of commercial execution and pipeline uncertainty has kept the stock in a relatively narrow, upward-trending range in recent months.
NVS Overview and Recent Performance
Novartis is a Swiss-based healthcare group focused on innovative prescription medicines, particularly in oncology, immunology, neuroscience, and cardiovascular disease, with its U.S.-listed shares trading as an American Depositary Receipt (ADR), a certificate representing shares in a foreign company. Its recent results reflect a company in transition. Novartis returned to modest net sales growth, but core operating income was roughly flat, and management reaffirmed guidance calling for only low-single-digit sales growth alongside a low-single-digit decline in core operating income for the year.
Novartis's growth engines remain impressive in isolation. Kisqali, a breast cancer treatment, grew more than 40% and crossed $1 billion in quarterly sales, while Kesimpta and Pluvicto also posted strong gains. However, these advances are being partly offset by the patent expiration of Entresto, a heart-failure medicine whose sales have fallen sharply amid generic competition. More significantly for sentiment, Novartis recently reported two consecutive late-stage clinical trial failures, triggering one of its sharpest single-day declines in decades and drawing public criticism from a major shareholder calling for board-level changes. This has injected considerable uncertainty into the near-term narrative.
Trending AI Robots
For traders seeking a data-driven edge across stocks like these, Tickeron's Trending AI Robots page offers a curated view of its best-performing AI trading bots. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, but only a small subset earns a place in this featured section. For example, the page highlights a select group of roughly 20 trending bots chosen from a much larger universe of more than 300, each with its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades. Metrics such as realized return, win rate, profit factor, and average trade duration help readers assess suitability for current market conditions. Explore the Trending AI Robots page to see which strategies are currently outperforming.
Head-to-Head Comparison
Although both companies operate in the same sector, their market positioning differs meaningfully. Amgen's business model blends mature blockbusters with fast-growing cardiometabolic and rare-disease therapies, plus a biosimilar portfolio that partially hedges patent risk. Novartis, by contrast, is more concentrated in oncology and immunology, with a smaller number of high-growth medicines offsetting losses from patent expirations. This gives Novartis greater exposure to the binary risk of clinical trials, as its recent pipeline setbacks illustrate.
On momentum, Amgen currently holds the edge. Its guidance raise and broad-based product growth contrast with Novartis's flat operating income and forward guidance for an earnings decline. Risk factors also diverge: Amgen faces biosimilar pressure and obesity-pipeline uncertainty, while Novartis confronts generic erosion of Entresto, trial-failure risk, and emerging governance pressure from shareholders. Valuation presents another trade-off, with Novartis trading at a lower forward price-to-earnings (P/E) multiple, a ratio comparing share price to expected earnings, reflecting the market's more cautious stance on its near-term outlook.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor AMGN over NVS in the current environment. Amgen's trend consistency is stronger, supported by consecutive estimate beats, a raised outlook, and diversified commercial momentum, whereas Novartis is contending with back-to-back trial failures, flat earnings, and growing investor scrutiny of its strategy. That said, this is a probabilistic assessment rather than a definitive forecast. Novartis's lower valuation and robust free cash flow could appeal if its pipeline stabilizes, while Amgen's premium multiple leaves less room for execution missteps. Relative positioning currently tilts in Amgen's favor, but both names carry meaningful, albeit different, sources of risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and NVS is a Hold.
AMGN in upward trend: 10-day moving average crossed above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 45 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 189 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMGN moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 26 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.318) is normal, around the industry mean (-2.799). P/E Ratio (27.081) is within average values for comparable stocks, (21.101). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.041) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
NVS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVS turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 32 of 45 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 42 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +1.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 184 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 158 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.914) is normal, around the industry mean (-2.799). P/E Ratio (22.657) is within average values for comparable stocks, (21.101). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.125) as compared to the industry average of (0.041). P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
AMGN | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 7 | |
SMR RATING 1..100 | 15 | 33 | |
PRICE GROWTH RATING 1..100 | 10 | 47 | |
P/E GROWTH RATING 1..100 | 25 | 22 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (10) in the Pharmaceuticals Major industry is significantly better than the same rating for AMGN (80) in the Biotechnology industry. This means that NVS’s stock grew significantly faster than AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (5) in the Biotechnology industry is in the same range as NVS (7) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is in the same range as NVS (33) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.
AMGN's Price Growth Rating (10) in the Biotechnology industry is somewhat better than the same rating for NVS (47) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than NVS’s over the last 12 months.
NVS's P/E Growth Rating (22) in the Pharmaceuticals Major industry is in the same range as AMGN (25) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | NVS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 57% | 3 days ago 54% |
| Stochastic ODDS (%) | 3 days ago 47% | 3 days ago 48% |
| Momentum ODDS (%) | 3 days ago 62% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 57% | 3 days ago 71% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 51% |
| Advances ODDS (%) | 11 days ago 61% | 4 days ago 55% |
| Declines ODDS (%) | 7 days ago 47% | 20 days ago 45% |
| BollingerBands ODDS (%) | 3 days ago 40% | 3 days ago 35% |
| Aroon ODDS (%) | 3 days ago 56% | 3 days ago 50% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- NVS’s TA Score: 6 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +1.57% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement